ImmixBio · pitchdeck
Immix Biopharma | Investor Presentation Deck | 62 slides
62 pages · 4 arc beats · 2 loops
Immix Biopharma | Investor Presentation Deck | 62 slides
ImmixBio · 2023-12 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
15101520253035404550556062
Deck intelligence map
4 coverage by narrative range · generated from this deck JSON
Narrative range 62 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Situation & Context 5 slides 100% 5/5 slides 100% 5/5 slides · 20 hits — 0/5 slides
40% 2/5 slides 40% 2/5 slides 100% 5/5 slides — 0/5 slides
Problem & Complication 9 slides 100% 9/9 slides 100% 9/9 slides · 49 hits — 0/9 slides
33.3% 3/9 slides 77.8% 7/9 slides 100% 9/9 slides — 0/9 slides
Evidence & Proof 20 slides 100% 20/20 slides 100% 20/20 slides · 93 hits — 0/20 slides
45% 9/20 slides 60% 12/20 slides 100% 20/20 slides 70% 14/20 slides · 24 hits Impact & Next Steps 28 slides 100% 28/28 slides 100% 28/28 slides · 135 hits — 0/28 slides
39.3% 11/28 slides · 12 hits 42.9% 12/28 slides 100% 28/28 slides — 0/28 slides
Slide inventory
62 every slide · same image gating as the playbook
03
The slide uses a numbered list format to present key value propositions for investors.summarize
Open slide detailBeat · Situation & Context
04
The slide uses a grid-based layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.other
Open slide detailBeat · Situation & Context
05
The slide uses a causal-chain framework to link platform capabilities to strategic outcomes.present_solution
Open slide detailBeat · Situation & Context
06
Includes a B-cell development diagram and a human anatomy map linking specific diseases to medical specialties.present_solution
Open slide detailBeat · Problem & Complication
07
The slide uses a hub-and-spoke diagram to connect a central problem (CAR-T Neurotoxicity) to four specific negative outcomes.frame_problem
Open slide detailBeat · Problem & Complication
08
The slide uses a structural diagram to highlight the substitution of the 'Tumor Binding Domain' with the 'COBRA Binder' in the NXC-201 molecule.present_solution
Open slide detailBeat · Problem & Complication
09
The slide uses a diagram to map specific protein domains to their functional benefits.present_solution
Open slide detailBeat · Problem & Complication
10
The slide uses external citations from Nature Medicine and Signal Transduction and Targeted Therapy to validate the scientific approach of ITAM modification.present_solution
Open slide detailBeat · Problem & Complication
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the superiority of the NXC-201 CD8 compare_peers
Open slide detailBeat · Problem & Complication
12
Includes a scientific quote justifying the use of Glycine/Serine linkers.present_solution
Open slide detailBeat · Problem & Complication
13
The slide uses a hub-and-spoke diagram to highlight four key clinical outcomes.present_solution
Open slide detailBeat · Problem & Complication
14
The slide explicitly notes that these are not head-to-head results and caution should be exercised in comparison.compare_peers
Open slide detailBeat · Problem & Complication
15
The slide uses a biological diagram to illustrate the structural difference of the N-GENIUS platform compared to competitors like Abecma and Carvykti.present_solution
Open slide detailBeat · Evidence & Proof
16
Includes comparative data points for transduction efficiency and experimental data for tonic signaling and anti-exhaustion.present_solution
Open slide detailBeat · Evidence & Proof
17
The slide uses a visual timeline comparison to highlight the clinical advantage of NXC-201's shorter side-effect profile.compare_peers
Open slide detailBeat · Evidence & Proof
18
The chart demonstrates a clear inverse relationship where the spike in HBI0101 cells corresponds to a rapid decline in dFLC levels, stabilizing around the 30-dashow_traction
Open slide detailBeat · Evidence & Proof
19
The slide uses a bottom-up summation approach to define the total eligible patient pool.size_opportunity
Open slide detailBeat · Evidence & Proof
20
The slide uses a causal chain to link cellular pathology to systemic organ damage.frame_problem
21
The slide uses a bar chart to compare hematologic and cardiac response rates across different therapies.compare_peers
22
The slide uses a table structure to contrast patient segments and includes a bar chart visualization for patient growth.compare_peers
23
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.compare_peers
24
Includes a footnote citing FDA approval precedents for similar single-arm studies.plan_implementation
25
Uses a visual icon-grid to represent market expansion.size_opportunity
26
Includes detailed clinical trial citations in the footer.compare_peers
27
The slide uses a two-column layout to separate milestones by drug candidate.plan_implementation
28
The slide uses a standard pharmaceutical pipeline table format.plan_implementation
29
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs. Allogeneic CAR-T and Bispecifics.argue_timing
30
The slide uses a stylized area chart to represent market segments and their respective valuations.size_opportunity
31
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.compare_peers
32
The table uses a cross-trial comparison format. The red dashed box highlights the key clinical data rows.compare_peers
33
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red/grey).compare_peers
34
The slide uses a side-by-side comparison of two disease indications, each with a list of clinical outcomes and a bottom section showing relevant market competitshow_traction
Open slide detailBeat · Evidence & Proof
35
The chart illustrates clinical trial efficacy data for NXC-201.show_traction
Open slide detailBeat · Impact & Next Steps
36
Includes a complex biological pathway diagram and three supporting charts (penetration depth, accumulation over time, and apoptosis efficacy).present_solution
Open slide detailBeat · Impact & Next Steps
37
The slide uses a numbered list format to present key value propositions.summarize
Open slide detailBeat · Impact & Next Steps
39
The slide uses a comparative layout to position NXC-201 as a superior, one-time monotherapy against current multi-drug, weekly treatment regimens.size_opportunity
Open slide detailBeat · Impact & Next Steps
40
The slide uses a step-wise process diagram to illustrate dose escalation.plan_implementation
Open slide detailBeat · Impact & Next Steps
41
The table displays clinical trial data for NXC-201, specifically focusing on safety profiles and management of side effects.analyze_data
Open slide detailBeat · Impact & Next Steps
42
The slide highlights specific safety data points for Arcellx's product, likely for competitive benchmarking purposes.compare_peers
Open slide detailBeat · Impact & Next Steps
44
The table compares clinical trial inclusion criteria across four different therapies, focusing on prior lines of therapy, toxicity recovery, ECOG status, and mecompare_peers
Open slide detailBeat · Impact & Next Steps
45
The slide highlights that NXC-201 has no exclusion for prior BCMA therapy, unlike the other listed treatments.compare_peers
Open slide detailBeat · Impact & Next Steps
46
The slide uses a bar chart to contrast the combined market size of two groups of drugs ($33.4bn vs $0.9bn).size_opportunity
Open slide detailBeat · Impact & Next Steps
47
Slide contains three distinct data charts comparing IMX-110 against standard treatments in mouse models.show_traction
Open slide detailBeat · Impact & Next Steps
48
Includes a process flow diagram illustrating the mechanism of action of iMX-110 in tumor microenvironments.show_traction
Open slide detailBeat · Impact & Next Steps
49
Includes unpublished internal data alongside referenced Winograd et al. 2015 study.show_traction
Open slide detailBeat · Impact & Next Steps
50
The slide compares two cohorts: Soft Tissue Sarcoma and Non-Sarcoma Cancers, using line charts for longitudinal change and bar charts for best response.show_traction
Open slide detailBeat · Impact & Next Steps
51
The slide uses a bubble chart to map clinical trial outcomes and a table to detail specific drug performance metrics across treatment lines.frame_problem
Open slide detailBeat · Impact & Next Steps
52
The chart on the left is a conceptual visualization rather than a standard data plot, emphasizing the 100% heavily pre-treated patient population.show_traction
Open slide detailBeat · Impact & Next Steps
53
The slide uses a process flow diagram to illustrate the clinical development path for two different treatment regimens.plan_implementation
Open slide detailBeat · Impact & Next Steps
54
Includes comparative size illustration of IMX-111 vs IgG antibody, and survival curve data.present_solution
Open slide detailBeat · Impact & Next Steps
55
Includes two sets of charts: tumor volume over time and survival curves for two different cancer models.show_traction
Open slide detailBeat · Impact & Next Steps
56
The slide uses a mix of mechanism-of-action diagrams, clinical trial bar charts, and preclinical mouse model data to validate the therapeutic approach.present_solution
Open slide detailBeat · Impact & Next Steps
57
The slide compares efficacy benchmarks of established competitors (AbbVie, J&J, Takeda) to set a baseline for the IMX-120 opportunity.compare_peers
Open slide detailBeat · Impact & Next Steps
58
The slide uses a side-by-side comparison structure to explain two distinct but complementary proprietary platforms.present_solution
Open slide detailBeat · Impact & Next Steps
59
The slide uses a process-flow style layout to connect platform capabilities to specific product outputs.present_solution
Open slide detailBeat · Impact & Next Steps
60
The process flow is non-linear, moving left-to-right on the top row (1-5) and right-to-left on the bottom row (6-10).plan_implementation
Open slide detailBeat · Impact & Next Steps
61
The slide uses a 3-pillar framework to explain the platform, then maps these to specific drug candidates with detailed mechanism-of-action descriptions.present_solution
Open slide detailBeat · Impact & Next Steps